Literature DB >> 28502444

Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications.

Praveen Kumar Conjeevaram Selvakumar1, Mohammad Nasser Kabbany1, Valerio Nobili2, Naim Alkhouri3.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome and has become the most common form of chronic liver disease in children and adolescents. The histologic spectrum of NAFLD is broad ranging, from the relatively benign form of simple steatosis to the aggressive form of nonalcoholic steatohepatitis, eventually leading to fibrosis and cirrhosis. NAFLD has also been recognized as an independent risk factor for extrahepatic complications, such as cardiovascular disease, type 2 diabetes mellitus, sleep disorders, and osteoporosis. In this review, we discuss both the hepatic and extrahepatic complications of NAFLD in children.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extrahepatic complications; Hepatic complications; Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity complications in children

Mesh:

Year:  2017        PMID: 28502444     DOI: 10.1016/j.pcl.2017.01.008

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  14 in total

Review 1.  Cardiovascular and Metabolic Complications - Diagnosis and Management in Obese Children.

Authors:  Naval K Vikram
Journal:  Indian J Pediatr       Date:  2017-12-08       Impact factor: 1.967

2.  Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Jay Shah; Toluwalase Okubote; Naim Alkhouri
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-07

Review 3.  Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter.

Authors:  Praveen Kumar Conjeevaram Selvakumar; Mohammad Nasser Kabbany; Naim Alkhouri
Journal:  Paediatr Drugs       Date:  2018-08       Impact factor: 3.022

4.  Angiopoietin-like 8 (ANGPTL8) as a potential predictor of NAFLD in paediatric patients with Prader-Willi Syndrome.

Authors:  C Mele; A Crinò; D Fintini; S Mai; A Convertino; S Bocchini; P Di Paolo; G Grugni; G Aimaretti; M Scacchi; P Marzullo
Journal:  J Endocrinol Invest       Date:  2020-10-16       Impact factor: 4.256

Review 5.  The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease.

Authors:  Sanjoy Roychowdhury; Praveen Conjeevaram Selvakumar; Gail A M Cresci
Journal:  Med Sci (Basel)       Date:  2018-06-05

Review 6.  The Liver in Children With Metabolic Syndrome.

Authors:  Ebe D'Adamo; Valeria Castorani; Valerio Nobili
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-02       Impact factor: 5.555

7.  Increased liver echogenicity and liver enzymes are associated with extreme obesity, adolescent age and male gender: analysis from the German/Austrian/Swiss obesity registry APV.

Authors:  Susanne Greber-Platzer; Alexandra Thajer; Svenja Bohn; Annette Brunert; Felicitas Boerner; Wolfgang Siegfried; Andreas Artlich; Anja Moeckel; Hildegunde Waldecker-Krebs; Sophie Pauer; Reinhard W Holl
Journal:  BMC Pediatr       Date:  2019-09-12       Impact factor: 2.125

8.  Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence: A protocol for a Bayesian network meta analysis.

Authors:  Yuli Sun; Zhaofeng Tan; Zhenyuan Jiang; Min Li; Weiqin Wang; Yaoyao Huang; Jianguang Sun
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

Review 9.  Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes.

Authors:  Serena Scapaticci; Ebe D'Adamo; Angelika Mohn; Francesco Chiarelli; Cosimo Giannini
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-06       Impact factor: 5.555

Review 10.  The Level of Vitamin D in Children and Adolescents with Nonalcoholic Fatty Liver Disease: A Meta-Analysis.

Authors:  Shanshan Zhu; Yuhui Wang; Fei Luo; Jie Liu; Liangchang Xiu; Jiheng Qin; Tao Wang; Na Yu; Hongfu Wu; Tangbin Zou
Journal:  Biomed Res Int       Date:  2019-07-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.